ESTRO 2025 - Abstract Book

S1547

Clinical – Mixed sites & palliation

ESTRO 2025

Conclusion: Risks of severe acute or late toxicity after SRT combined with BCT were low (<10%), in both the prospective and retrospective cohort. Treatment with uninterrupted BCT during SRT did not result in significantly increased rates of severe toxicity. Toxicity was higher in the prospective compared to the retrospective cohort, suggesting potential recall bias, indicating the value of prospective data collection for toxicity assessment.

Keywords: SRT, targeted therapy, immunotherapy

References: 1. Kroeze SGC, Pavic M, Stellamans K, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol 2023; 24(3): e121-e32. 2. Kroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treat Rev 2017; 53: 25-37.